Be Prepared For An Acute Digoxin Ingestion Of An Unknown Amount

DigiFab®
Digoxin Immune Fab (Ovine)

Please scroll down for link to full prescribing information.
**IMS Data Shows Digoxin Use Has Remained Relatively Steady**

**Over 16 Million Digoxin Prescriptions written in 2006**

**Reported Digoxin Toxicities are 10.5% higher than 10 years earlier**

**AAPCC Data Reveals Toxic Exposures Continue To Rise Among Adults**

AAPCC defines an adult exposure in patients >19 years old.

**Several Studies have found that only 20-30% of emergency department patients with poisoning exposures are reported to US Poison Centers.**

**As Digoxin has a narrow therapeutic range, toxicity in various degrees is common and has historically been reported in 26%-29% of all patients.**

---

Identify the Signs of Digoxin Toxicity

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Acute Digoxin Intoxication</th>
<th>Chronic Digoxin Intoxication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptoms</td>
<td>Nausea and vomiting most consistent findings: diarrhea occasionally observed</td>
<td>Anorexia, nausea, vomiting, headache, malaise, fatigue, weakness, drowsiness common; paresthesias, confusion, disorientation, aphasia, delirium, hallucinations, visual disturbances sometimes reported; convulsions rarely</td>
</tr>
<tr>
<td>ECG findings</td>
<td>ECG may indicate supraventricular arrhythmias, in general, with heart block and bradycardia most common; generally, ventricular arrhythmias rare</td>
<td>All types of arrhythmias have been reported; most common are: nonparoxysmal nodal tachycardia, atrial tachycardia with AV dissociation, bidirectional ventricular tachycardia</td>
</tr>
<tr>
<td>Potassium</td>
<td>Normal or increased, depending on magnitude of overdose and time course</td>
<td>Normal to decreased, depending on use of diuretics, nutritional status, and presence of the other factors known to affect potassium levels</td>
</tr>
<tr>
<td>Serum digoxin</td>
<td>High levels always expected</td>
<td>Levels may be in therapeutic range but are usually elevated; borderline normal values may represent toxicity</td>
</tr>
</tbody>
</table>

Antidotes Such As DigiFab® Digoxin Immune Fab (Ovine) Can Be Lifesaving When Used At The Appropriate Time

DigiFab® Digoxin Immune Fab (Ovine) is indicated for the treatment of patients with life-threatening or potentially life-threatening digoxin toxicity or overdose. DigiFab® is indicated for the same conditions as Digibind®*. Clinical claims, indications and usage of DigiFab® are IDENTICAL to Digibind®. Neither product is indicated for milder cases of digitalis toxicity.

IMPORTANT SAFETY INFORMATION

Based on experience with Digibind®, the following adverse reactions could occur with the use of DigiFab®:

Exacerbation of low cardiac output states and congestive heart failure due to the withdrawal of inotropic effect of digitalis; hypokalemia due to reactivation of the sodium-potassium ATPase; rapid ventricular response in patients with atrial fibrillation due to the withdrawal of the effects of digitalis on the atrioventricular node and rare allergic reactions. Patients with allergies to papain, chymopapain, other papaya extracts or the pineapple enzyme bromelain may be at risk for an allergic reaction to DigiFab. DigiFab is an animal protein, monitor for delayed allergic reactions and hypersensitivity.

Suicidal ingestion may involve more than one drug. Toxic effects of other drugs or poisons should not be overlooked. In the clinical trials of DigiFab, 6 of 15 patients in the digoxin overdose study had a total of 17 adverse experiences, most were mild to moderate in nature and all were deemed “remotely associated” with DigiFab. Three events were deemed “severe”, all occurred in one patient and consisted of the following: pulmonary edema, bilateral pleural effusion and renal failure. After reviewing the case, it was determined that these events were likely due to the loss of digoxin inotropic support in combination with the patient’s underlying medical condition. Of 8 healthy volunteers who received DigiFab, only 2 experienced an adverse reaction that was considered to be associated with DigiFab. The reactions were 1 episode of phlebitis of the infusion vein and 1 episode of moderate postural hypotension, which became mild prior to resolving.

Click here for full prescribing information.

* Reference: DigiFab® product monograph

** Digibind® is a registered trademark of GlaxoSmithKline. Neither GlaxoSmithKline nor Digibind® are related or affiliated with Nycomed US Inc.
20 vials of DigiFab® (Digoxin Immune Fab (Ovine)) administered all at one time is the recommended dosage for an acute digoxin ingestion of an unknown amount.

Ensure that your inventory levels for DigiFab® are where they need to be. DigiFab® Digoxin Immune Fab (Ovine), the cost-saving treatment for life-threatening digoxin toxicity may save your hospital as much as $80 - $120 per vial over the competition. For current price information call Customer Service at 1-800-645-9833.

DigiFab® is Widely Available On Most Group Purchasing Contracts.

Click here for full prescribing information.

Use this convenient scannable bar code to assist you when ordering.